ISSN: 2574 -1241



Takotsubo Cardiomyopathy After 3rd Dose of mRNA COVID-19 Vaccination: A Case Report

Hani Karameh*, Arik Wolak and Elad Asher

The Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Israel

*Corresponding author: Hani Karameh, The Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel



Received: 🕮 June 06, 2022

Published: 🕮 June 15, 2022

Citation: Hani Karameh, Arik Wolak and Elad Asher. Takotsubo Cardiomyopathy After 3rd Dose of mRNA COVID-19 Vaccination: A Case Report. Biomed J Sci & Tech Res 44(4)-2022. BJSTR. MS.ID.007075.

ABSTRACT


Background: Third dose of SARS-CoV-2 vaccine is a new strategy to fight COVID-19 variants, we report a case of acute Takotsubo Cardiomyopathy (TC) following vaccination. 90-year-old woman presented with sudden shortness of breath following her vaccination, echocardiogram showed apical ballooning with new reduction in left ventricular ejection fraction, emergent coronary angiogram showed no coronary artery disease. Cardiac magnetic resonance imaging confirmed TC Diagnosis of vaccine associated Takotsubo was made given the temporal relationship and absence of other triggers. TC may occur after booster COVID-19 vaccination and being aware of this this potential life-threatening rare association is essential for evaluating vaccine safety.

Objective: Takotsubo Cardiomyopathy (TC) should be considered in patients who present with cardiac symptoms within days of receiving mRNA BNT162b2 SARS-CoV-2 vaccination, especially after the third dose. Further studies are warranted to determine the mechanisms by which mRNA vaccines may cause Cardiomyopathy and for potential long-term cardiovascular injury.

Keywords: Takotsubo; Cardiomyopathy; Third Dose; mRNA Vaccine; COVID-19; Case Report

Case Report

A 90-year-old woman with past medical history of hypertension, hyperlipidemia, chronic kidney disease and post transcatheter aortic valve replacement (TAVR). She was admitted to the emergency department due to sudden onset of dyspnea which started 1 day after receiving the third dose of BNT162b2 mRNA Pfizer vaccine, she had no chest pain, palpitations, cough or fever. She reported no symptoms after her second dose of the vaccine which she received 6 months prior to the third dose. On presentation she was hypoxic with 79% on room airand diffuse lung crepitations on auscultation, heart sounds were normal with holosystolic murmur consistent with mitral regurgitation. A chest x-ray showed pulmonary edema. Initial laboratory tests revealed elevated levels of high-sensitivity troponin I at 186 ng/L (n <6 ng/L) which further peaked to 9415 ng/L in the next 12 hours. An ECG showed mild ST segment elevation in leads V2-4 (Figure 1). Invasive coronary angiography ruled out obstructive coronary artery disease (Figure 2). Transthoracic echocardiogram showed apical ballooning (Figure 3) with estimated left ventricular ejection fraction of 35-39%. TC was further confirmed by cardiac magnetic resonance imaging (CMR) that showed edema in mid-apical region with increased relaxation time from basal to apical level (Figure 4). The patient showed good improvement and recovery in her clinical condition and was discharged in a stable condition.



- **Figure 1:** A. ECG recording at presentation which showing LVH with Q waves in anterior leads.
- ECG recording at the third day of hospitalization showing inverted symmetrical T-waves in all precordial leads. B.



Figure 2:

- A) Right coronary artery without evidence of obstructive lesions.
- B) left coronary artery without evidence of obstructive lesion in any segment.




Figure 3: Transthoracic echocardiogram showing apical ballooning.




Figure 3: Cardiac Magnetic Resonance – Native T1 mapping showing increasing relaxation time from base to apex.

- Long view Apex-level Mid-level (A)
- (B)
- (C)
- Basal level. (D)

Discussion

To the best of our knowledge, this the first case to describe TC following the 3rd dose of vaccination for COVID-19. This highlights a rare but serious cardiovascular event occurring shortly after COVID-19 vaccination. Previous reports suggested an association of the second dose of mRNA-1273 SARS-CoV-2 vaccine [3] and after influenza vaccination with TC [4,5]. The third dose of mRNA vaccine (COVID-19 vaccine booster) is the new strategy in to cope with the COVID-19 pandemic. While healthcare professionals are encouraging the population to receive the booster vaccine in hope that a critical mass of vaccinations could avert a national lockdown to stem the spread of the ultra-contagious new variants of the coronavirus, it will be important to follow-up these unusual events to better understand the reactions to COVID-19 3rd vaccination.

Conflict of Interest

None declared.

Funding

None declared.

References

- 1. (2021) WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: WHO.
- 2. (2021) Association AHAAS. COVID-19 vaccine benefits still outweigh risks, despite possible rare heart complications: Statement from the American Heart Association/American Stroke Association: AHA.
- Boscolo Berto M, Spano G, Wagner B, Bernhard B, Häner J, et al. (2021) Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination. Heart Lung Circ 30(12): e119-e120.
- Singh K, Marinelli T, Horowitz JD (2013) Takotsubo cardiomyopathy after anti-influenza vaccination: catecholaminergic effects of immune system. Am J Emerg Med 31: 1627.
- Santoro F, Ieva R, Ferraretti A, Carpagnano G, Pappalardo I, et al. (2013) Tako-Tsubo cardiomyopathy after influenza vaccination. Int J Cardiol 167(2): e51-52.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2022.44.007073 Hani Karameh. Biomed J Sci & Tech Res



This work is licensed under Creative *Commons* Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

https://biomedres.us/